Hong Kong Stock Market Surges | XianSheng Pharmaceutical (02096.HK) Rises Nearly 3% Its self-developed Pol inhibitor SIM0508 has obtained clinical approval for use in combination with olaparib.

According to the China Fortune Financial APP, Sinovac Biotech (02096.HK) rose by nearly 3%, as of the deadline, it rose by 2.58%, to 12.7 Hong Kong dollars, with a trading volume of 55.6295 million Hong Kong dollars.